Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arimidex more effective than tamoxifen for breast cancer treatment
At a median follow-up of 100 months, more than three years after the completion of treatment, Arimidex significantly reduced the risk of recurrence in comparison with tamoxifen in
At a median follow-up of 100 months, more than three years after the completion of treatment, Arimidex significantly reduced the risk of recurrence in comparison with tamoxifen in
Ocimum has assumed certain liabilities associated with the genomics assets and business. The Gene Logic name transfers to Ocimum Biosolutions and the company, formerly named Gene Logic, now
Results from the Phase III HALT breast cancer 135 study showed that denosumab, a fully human monoclonal antibody under investigation as a twice yearly subcutaneous injection, increased bone
In the preclinical rodent study, donor adipose-derived stem and regenerative cells, or saline, was combined with donor adipose tissue and then transplanted onto recipient skulls. After six and
The comparison study assessed 465 patients with hormone receptor-positive breast cancer from a previous Eastern Cooperative Oncology Group (ECOG) study, computing both the Adjuvant Online risk estimate and
Duramed has initiated patent litigation in the US District Court of New Jersey seeking injunctive relief. Bruce Downey, chairman and CEO of Barr, said: “We believe that Watson’s
The new algorithm, which has been incorporated into Varian’s Eclipse treatment planning software, makes it possible to plan for intensity modulated proton therapy by optimizing dose distributions in
Kamada’s Transferrin has potential for utilization in the pharmaceutical industry as a targeting molecule for highly metabolizing cells with high iron requirement (cancerous or infected) cells. Kamada, which
The Japanese study was conducted over the course of a 20-month period, where a group of 15 amnestic mild cognitive impairment (MCI) patients with essential hypertension were divided
In the multi-center, open-label trial designed to investigate the activity of a short non-anthracycline-based preoperative treatment for early breast cancer in both HER2-negative and HER2-positive patients, promising results